Organic compounds

1. A compound of the formula (I)

where

R 1 is substituted or unsubstituted oxazolyl, indolyl, pyrrolyl, pyrazolyl, triazinyl, 2-oxodihydrobenzo[d][1,3]oxazinyl, 4-oxodihydroimidazolyl, 5-oxo-4H-[1,2,4]triazinyl, 3-oxo-4H-benzo[1,4]thiazinyl, tetrahydroquinoxalinyl, 1,1,3-trioxodihydro-2H-1λ 6 -benzo[1,4]thiazinyl, 1-oxo-pyridyl, dihydro-2H-benzo[1,4]oxazinyl, 2-oxotetrahydrobenzo[e][1,4]diazepinyl, 2-oxodihydrobenzo[e][1,4]diazepinyl, 1H-pyrrolizinyl, phthalazinyl, 1-oxo-3H-isobenzofuranyl, 4-oxo-3H-thieno[2,3-d]pyrimidinyl, 3-oxo-4H-benzo[1,4]oxazinyl, [1,5]naphthyridyl, dihydro-2H-benzo[1,4]thiazinyl, 1,1-dioxodihydro-2H-benzo[1,4]thiazinyl, 2-oxo-1H-pyrido[2,3-b][1,4]oxazinyl, dihydro-1H-pyrido[2,3-b][1,4]oxazinyl, 1H-pyrrolo[2,3-b]pyridyl, benzooxazolyl, 2-oxobenzooxazolyl, 2-oxo-1,3-dihydroindolyl, 2,3-dihydroindolyl, indazolyl, benzofuranyl, dihydrobenzofuranyl, tetrahydropyranyl, 2-oxopiperidinyl or 2-oxoazepanyl;

R 2 is phenyl substituted by 1-3 hydroxyl, cyano, trifluoromethyl, C 1-6 -alkyl, halo-C 1-6 -alkyl, hydroxy-C 1-6 -alkyl, C 1-6 -alkoxy-C 1-6 -alkyl, cyano-C 1-6 -alkyl, carboxy-C 1-6 -alkyl, C 1-6 -alkanoyloxy-C 1-6 -alkyl, C 1-6 -alkoxycarbonyloxy-C 1-6 -alkyl, C 1-6 -alkoxycarbonyl, or C 1-6 -alkoxy groups, or by a C 1-6 -alkylenedioxy group, and/or by an L1-T1-L2-T2-L3-T3-L4-T4-L5-U radical;

L1, L2, L3, L4 and L5 are each independently a bond, C 1-8 -alkylene, C 2-8 -alkenylene or C 2-8 -alkynylene, or are absent;

T1, T2, T3 and T4 are each independently

(a) a bond, or are absent, or are one of the groups

(b) CH(OH)—

(c) —CH(OR 6 )—

(d) —CH(NR 5 R 6 )—

(e) —CO—

(f) —CR 7 R 8 —

(g) —O— or —NR 6 —

(h) —S(O) 0-2 —

(I) —SO 2 NR 6 -

(j) —NR 6 SO 2 —

(k) —CONR 6 -

(l) —NR 6 CO—

(m) —O—CO—

(n) —CO—O—

(o) —O—CO—O—

(p) —O—CO—NR 6 -

(q) —N(R 6 )—CO—N(R 6 )—

(r) —N(R 6 ) —CO—O—

(s) pyrrolidinylene, piperidinylene or piperazinylene

(t) —C(R 11 )(R 12 )—,

where the bonds starting from (b)-(t) lead to a saturated or aromatic carbon atom of the adjacent group if the bond starts from a heteroatom, and where not more than two (b)-(f) groups, three (g)-(h) groups and one (i)-(t) group are present;

R 3 is hydrogen;

R 4 is hydrogen;

R 5 and R 6 are each independently hydrogen, C 1-6 -alkyl, C 2-6 -alkenyl, aryl-C 1-6 -alkyl or acyl, or, together with the nitrogen atom to which they are bonded, are a 5- or 6-membered heterocyclic ring which may contain an additional nitrogen, oxygen or sulphur atom or a —SO— or —SO 2 -group, and the additional nitrogen atom may optionally be substituted by C 1-6 -alkyl radicals;

R 7 and R 8 , together with the carbon atom to which they are bonded, are a 3-7-membered ring which may contain one or two —O— or —S— atoms or —SO— or —SO 2 — groups;

R 9 is hydrogen, C 1-6 -alkyl, C 1-6 -alkoxy-C 1-6 -alkyl, acyl or arylalkyl;

R 11 is hydrogen or C 1-6 -alkyl;

R 12 is hydrogen or C 1-6 -alkyl;

U is hydrogen, C 1-6 -alkyl, C 3-8 -cycloalkyl, cyano, optionally substituted C 3-8 -cycloalkyl, aryl, or heterocyclyl;

Q is absent;

X is a —O—CHR 11 - group;

W is oxygen or sulphur;

Z is C 1-6 -alkylene, C 2-6 -alkenylene, hydroxy-C 1-6 -alkylidene, —O—, —S—, —O-alk-, —S-alk-, -alk-O—, -alk-S— or -alk-NR 9 —, where alk is C 1-6 -alkylene;

n is 0; and

m is 0;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 of the formula (IA)

where R 1 , R 2 , R 3 , R 4 , Q, W, X, Z, n and m are each as defined for the compounds of the formula (I) according to claim 1 .

3. A compound according to claim 1 or 2 where R 1 , R 3 , R 4 , R 11 , R 12 , Q, X, W, m and n are as defined in claim 1 ; R 2 is phenyl substituted by hydroxyl, cyano, trifluoromethyl, C 1-6 -alkyl, halo-C 1-6 -alkyl, hydroxy-C 1-6 -alkyl, C 1-6 -alkoxy-C 1-6 -alkyl, cyano-C 1-6 -alkyl, carboxy-C 1-6 -alkyl, C 1-6 -alkanoyloxy-C 1-6 -alkyl, C 1-6 -alkoxycarbonyloxy-C 1-6 -alkyl, C 1-6 -alkoxycarbonyl, C 1-6 -alkoxy, C 1-6 -alkylenedioxy, or by an L1-T1-L2-T2-L3-T3-L4-T4-L5-U radical; L1, L2, L3, L4 and L5 are each independently a bond, C 1-8 -alkylene, C 2-8 -alkenylene or C 2-8 -alkynylene, or are absent;

T1, T2, T3 and T4 are each independently

(a) a bond, or are absent, or are one of the groups

(b) —CH(OH)—

(c) —CH(OR 6 )—

(d) —CH(NR 5 R 6 )—

(e) —CO—

(f) —CR 7 R 8 -

(g) —O— or —NR 6 -

(h) —S(O) 0-2 —

(I) —SO 2 NR 6 -

(j) —NR 6 SO 2 —

(k) —CONR 6 -

(l) —NR 6 CO—

(m) —O—CO—

(n) —CO—O—

(o) —O—CO—O—

(p) —O—CON—R 6 -

(q) —N(R 6 )—CO—N(R 6 )—

(r) —N(R 6 ) —CO—O—

(s) pyrrolidinylene, piperidinylene or piperazinylene

(t) —C(R 11 )(R 12 )—,

where the bonds starting from (b)-(t) lead to a saturated or aromatic carbon atom of the adjacent group if the bond starts from a heteroatom, and where not more than two (b)-(f) groups, three (g)-(h) groups and one (i)-(t) group are present;

R 5 and R 6 are each independently hydrogen, C 1-6 -alkyl or acyl, or, together with the nitrogen atom to which they are bonded, are a 5- or 6-membered heterocyclic ring which may contain an additional nitrogen, oxygen or sulphur atom;

R 7 and R 8 , together with the carbon atom to which they are bonded, are a 3-7-membered ring which may contain one or two —O— or —S— atoms;

U is hydrogen, C 1-6 -alkyl, C 3-8 -cycloalkyl, cyano, aryl or heterocyclyl; and

Z is C 1-6 -alkylene or -alk-O—;

or a pharmaceutically acceptable salt thereof.

4. A compound according to claim 1 , wherein R 1 is 3-C 1-6 -alkylindolyl, benzofuranyl, 4H-benzo[1,4]oxazin-3-onyl, 3,4-dihydro-2H-benzo[1,4]oxazinyl, 3,4-dihydro-2H-benzo[1,4]thiazinyl, 3,3-di-C 1-6 -alkyl-1,3-dihydroindol-2-onyl, 3,3-di-C 1-6 -alkyl-1,3-dihydroindolyl, indolyl, 3-methylindolyl and spiro[cyclopropane-1,3′]-2,3-dihydro-1H-indolyl, each of which may in particular be substituted by at least one substituent selected from C 1-6 -alkoxy-C 1-6 -alkoxy, C 1-6 -alkoxy-C 1-6 -alkyl, N-acetyl-C 1-6 -alkoxy-C 1-6 -alkylamino, C 1-6 -alkanoylamido-C 1-6 -alkyl, N—C 1-6 -alkyl-C 1-6 -alkanoylamido-C 1-6 -alkyl, C 1-6 -alkoxy-C 1-6 -alkoxy-C 1-6 -alkyl, triazol-1-yl-C 1-6 -alkyl, tetrazol-1-yl-C 1-6 -alkyl, tetrazol-2-yl-C 1-6 -alkyl, tetrazol-5-yl-C 1-6 -alkyl, C 1-6 -alkoxycarboxyl-C 1-6 -alkyl, pyrrolidinonyl-C 1-6 -alkyl, imidazolyl-C 1-6 -alkyl, cyano-C 1-6 -alkyl, carboxy-C 1-6 -alkyl, carboxy-C 1-6 -alkoxy, C 1-6 -alkoxycarbonyl-C 0-6 -alkyl, C 1-6 -alkylsulphonamidyl-C 1-6 -alkyl, C 1-6 -alkoxy-C 1-6 -alkanoylamido, C 1-6 -alkoxy-C 1-6 -alkanoylamido-C 1-6 -alkyl, N—(C 1-6 -alkyl)-C 1-6 alkoxy-C 1-6 -alkanoylamido, C 1-6 -alkoxy-C 1-6 -alkylcarbamoyl-C 1-6 -alkyl, C 3-8 -cycloalkanoylamido-C 1-6 -alkyl, C 1-6 -alkylaminocarbonylamino-C 1-6 -alkyl, C 1-6 -alkanoylamidomethylpyrrolidinyl, N—(C 1-6 -alkoxy-C 1-6 -alkyl)carbamoyl, N—(C 1-6 -alkoxy-C 1-6 -alkyl)-N—(C 1-6 -alkyl)carbamoyl, N—(C 1-6 alkoxy-C 1-6 -alkyl)imidazol-2yl, hydroxy-C 1-6 -alkyl, hydroxy-C 1-6 -alkoxym hydroxy-C 1-6 -alkoxy-C 1-6 alkyl, C 1-6 -alkoxycarbonylamido-C 1-6 -alkyl, amino-C 1-6 -alkyl and C 1-6 -alkylamino-C 1-6 -alkyl.

5. A compound according to claim 1 , wherein R 2 is phenyl substituted by C 1-6 -alkoxybenzyloxy-C 1-6 -alkoxy, C 1-6 -alkoxyphenyl-C 1-6 -alkoxy-C 1-6 -alkoxy, C 1-6 -alkylphenoxy-C 1-6 -alkoxy, halobenzyloxy-C 1-6 -alkoxy, halophenoxy-C 1-6 -alkoxy, halophenoxy-C 1-6 -alkoxy-C 1-6 -alkyl, N-(halophenyl)pyrrolidin-3-yloxy or indol-4-yloxy-C 1-6 -alkyl.

6. A pharmaceutical preparation comprising a compound of the formula (I) or (IA) or salt according to claim 1 or 2 , and a pharmaceutically inert excipient.

7. A method for treatment of hypertension, glaucoma, cardiac infarction, or restenoses, which comprises administering an effective amount of a compound or salt according to claim 1 or 2 to a patient in need thereof.

8. A method for the preparation of a pharmaceutical composition comprising a compound of the formula (I) or (IA) or salt according to claim 1 or 2 , and a pharmaceutically inert excipient, which comprises admixing a compound or salt according to claim 1 or 2 with a pharmaceutically inert excipient.